Wnt Surrogate Antibody Program
Diabetic Macular Edema (DME), wet Age-Related Macular Degeneration (wAMD)
Key Facts
About NeuVasQ
NeuVasQ is a private, preclinical-stage biotech based in Gosselies, Belgium, founded in 2018. The company is developing a novel class of therapeutic antibodies designed to activate the Wnt signaling pathway specifically at the neurovascular unit to repair leaky blood-brain and blood-retina barriers. Its initial focus is on major ophthalmic indications—diabetic macular edema (DME) and wet age-related macular degeneration (wAMD)—with potential expansion into neurological conditions. The company is led by an experienced executive director and is actively presenting preclinical data at scientific conferences.
View full company profileAbout NeuVasQ
NeuVasQ is a private, preclinical-stage biotech based in Gosselies, Belgium, founded in 2018. The company is developing a novel class of therapeutic antibodies designed to activate the Wnt signaling pathway specifically at the neurovascular unit to repair leaky blood-brain and blood-retina barriers. Its initial focus is on major ophthalmic indications—diabetic macular edema (DME) and wet age-related macular degeneration (wAMD)—with potential expansion into neurological conditions. The company is led by an experienced executive director and is actively presenting preclinical data at scientific conferences.
View full company profile